Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01603394 · ClinicalTrials.gov registry record · Phase 4

Pilot Study Of Pregabalin And Prediction Of Treatment Response In Patients With Postherpetic Neuralgia

A Phase 4 study, sponsored by Pfizer.

Terminated
Registry status
Phase 4
Development phase
9
Enrollment target

NCT01603394 is a Phase 4 study that was terminated before completion, run by Pfizer. The registered enrollment target is 9 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01603394, a Phase 4 study, was terminated before completion, sponsored by Pfizer.

TERMINATED
Registry status
Phase 4
Development phase
9 participants
Enrollment target

Study Summary

The primary objective is to explore whether sensory symptom cluster analysis is useful for predicting treatment response in Postherpetic Neuralgia.

Interventions

  • DRUG pregabalin

Trial Details

FieldValue
Enrollment Target 9 participants
Start Date 2012-10
Est. Completion 2013-06
Phase Phase 4

Sponsor

Pfizer

1,845 total trials

What the Registry Record Tells You About NCT01603394

The ClinicalTrials.gov registry entry for NCT01603394 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which pregabalin is the first listed.

NCT01603394 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT01603394 about?

NCT01603394 is a clinical study titled "Pilot Study Of Pregabalin And Prediction Of Treatment Response In Patients With Postherpetic Neuralgia". The primary objective is to explore whether sensory symptom cluster analysis is useful for predicting treatment response in Postherpetic Neuralgia.

What is the current status of trial NCT01603394?

This trial is currently terminated. It is a Phase 4 study. The enrollment target is 9 participants. The study started on 2012-10. Estimated completion is 2013-06.

What interventions are being tested in trial NCT01603394?

The interventions under investigation include: pregabalin (DRUG).

Who is sponsoring clinical trial NCT01603394?

This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.